The entire world of investing is admittedly an enormous case study in abnormal psychology, but biotech seems to have a bit more than its share. For instance, there are not too many other sectors where a large portion of investors actively ignore companies with established records of success in favoring of betting on awful little companies with collectively minimal chances of success.
So although I realize it would probably be better for my pageview numbers to review another sub-$5 oncology biotech wannabe, I am instead going to look at Celgene (CELG). Celgene shares are not what I would call cheap, but the odds of Celegene (still) being a successful company in 2020 is quite a bit better than for the majority of biotech stocks.
Continue reading here:
Expensive Celgene Shares A Better Bet Than Most Biotechs
No comments:
Post a Comment